Can-Fite BioPharma (CANF) Price to Earnings (2016 - 2023)

Can-Fite BioPharma (CANF) posted Price to Earnings of 452.27 for Q3 2017, up 7.19% quarter-over-quarter from 421.94 in Q2 2017.

Analysis

Can-Fite BioPharma (CANF) Price to Earnings (2016 - 2023) Analysis & Trends

Can-Fite BioPharma (CANF) has 2 years of Price to Earnings data on file, last reported at 452.27 in Q3 2017.

For the quarter ending Q3 2017, Price to Earnings changed N/A year-over-year to 452.27; the trailing twelve-month figure through Sep 2017 stood at 452.27 (changed N/A YoY), and the FY2016 full-year result was 598.66, changed N/A from the prior year.
Price to Earnings was 452.27 for Q3 2017 at Can-Fite BioPharma, up from 421.94 in the prior quarter.
In the past five years, Price to Earnings ranged from a high of 792.44 in Q1 2017 to a low of 421.94 in Q2 2017.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	651.77 Bn	631.01 Bn	17.26 Bn
2	AbbVie	447.56 Bn	440.99 Bn	12.70 Bn
3	Merck	364.58 Bn	357.44 Bn	12.21 Bn
4	Novartis Ag	268.98 Bn	261.29 Bn	11.24 Bn
5	Pfizer	158.03 Bn	146.33 Bn	10.94 Bn
6	Sanofi	52.29 Bn	44.91 Bn	10.79 Bn
7	Revolution Medicines	43.18 Bn	43.18 Bn	-
8	Incyte	25.12 Bn	20.58 Bn	1.57 Bn
9	United Therapeutics	21.67 Bn	19.01 Bn	683.80 Mn
10	Can-Fite BioPharma	1.83 Mn	-1.16 Mn	-

Historic Data

Download Data